What are HBV capsid assembly inhibitor drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HBV capsid assembly inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting HBV core antigen (HBcAg)). 0 are currently marketed, with 2 more in clinical development.

HBV capsid assembly inhibitor

0 marketed 2 in Phase 3

This page covers all HBV capsid assembly inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HBV core antigen (HBcAg), HBV core antigen (capsid assembly).

Targets

HBV core antigen (HBcAg) · HBV core antigen (capsid assembly)

Phase 3 pipeline (2)

ASC40 · Ascletis Pharmaceuticals Co., Ltd. · Virology / Hepatology
ASC40 is a hepatitis B virus (HBV) capsid assembly modulator that disrupts viral particle formation.
ASC40 tablets · Ascletis Pharmaceuticals Co., Ltd. · Virology / Hepatology
ASC40 is a hepatitis B virus (HBV) capsid assembly modulator that disrupts viral particle formation.

Patent intelligence

hbv capsid assembly inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates